TP53 and lymphoma: ONC201 is a stable, orally active, blood brain barrier-penetrable compound that has demonstrated p53-independent anti-cancer activity as a monoagent and a combination in several preclinical models that include glioblastoma, breast cancer, colon cancer, lung cancer, lymphoma, and other tumors [1, 10, 11].